Gene therapy for sickle cell disease passes key preclinical test — Harvard Gazette
$ 15.99 · 4.7 (580) · In stock
A precision-engineered gene therapy virus, inserted into blood stem cells that are then transplanted, markedly reduced sickle-induced red-cell damage in mice with sickle cell disease, researchers from Dana-Farber/Boston Children’s Cancer and Blood Disorders Center reported in the Journal of Clinical Investigation.
World-first gene therapy for 2 blood disorders — sickle cell and thalassemia — approved
Health Archives — Page 34 of 107 — Harvard Gazette
Gene therapy for sickle cell disease: moving from the bench to the bedside - ScienceDirect
PDF) Editing Human DNA Moral and social implications of germline genetic modification
gene therapy, The Stem Cellar
Gene therapy for sickle cell disease passes key preclinical test — Harvard Gazette
SEC Filing CRISPR Therapeutics
CRISPR Sickle Cell Gene Therapy: Approaches, Challenges, and Progress
Gene therapy for sickle cell disease passes key preclinical test — Harvard Gazette
SEC Filing CRISPR Therapeutics
New study shows promising evidence for sickle cell gene therapy - UChicago Medicine